WTA2

Sigma-Aldrich

Complete Whole Transcriptome Amplification Kit

DNA polymerase included, Complete Kit with optimized enzyme to amplify total RNA in <4 hours, no 3′ bias

NACRES:
NA.55
Pricing and availability is not currently available.

application(s)

whole genome amplification: suitable

shipped in

wet ice

storage temp.

−20°C

General description

WTA2 is optimized to amplify RNA from formalin-fixed, paraffin-embedded (FFPE) and other damaged or degraded samples. Whole Transcriptome Amplification (WTA) technology, allows for representative amplification of low nanogram quantities of total RNA in less than 4 hours without 3′-bias. Amplification products are suitable for applications such as qPCR, micro array analysis, and cloning. The WTA2 kit contains the polymerase needed to amplify the cDNA library.

Application

Complete Whole Transcriptome Amplification Kit is used for the following applications:
  • To establish a protocol for the simultaneous analysis of DNA and RNA viruses present in pig faeces. (Simultaneous identification of DNA and RNA viruses present in pig faeces using process controlled deep sequencing)
  • Reverse transcription and cDNA amplification
  • For the synthesis and amplification of cDNA library using Genomic RNA released from immunocaptured PPV particles
  • Nucleic Acid Preparation and Deep Sequencing (The extracted nucleic acids were randomly primed for cDNA synthesis)
Suitable for use with downstream applications including:
  • qPCR
  • microarray analysis
  • cloning

Features and Benefits

  • Achieve up to 10,000x amplification in less than 4 hours with less than 30 minutes of "hands on" time required
  • Only 20 pg of total RNA template is required to amplify suitable cDNA for microarray profiling
  • Contains all needed components for cDNA amplification
  • Achieve linear amplification of expressed genes and exons without 3′ or 5′ bias
  • Effectively amplifies single cell or low input RNA, including mRNA and total RNA from any animal, plant, or microorganism

Principle

The WTA2 process involves two steps. In the first step, sample RNA is reverse transcribed with non-self-complementary primers composed of a quasi-random 3′ end and a universal 5′ end. During this process, displaced single strands serve as new templates for primer annealing and extension. The resultant cDNA library, comprised of random, overlapping 100 - 1000 base fragments flanked by universal end sequence. The 2nd step amplifies the cDNA library by PCR using WTA2 polymerase and a universal end primer to produce WTA2 product.

Kit Components Also Available Separately

Product No.
Description
SDS

  • Library Synthesis Enzyme

  • Library Synthesis Solution

  • Amplification Mix

  • Library Synthesis Buffer

  • W4502Water, Nuclease-Free Water, for Molecular Biology

  • Amplification Enzyme

  • D7295Deoxynucleotide Mix, 10 mM, Molecular Biology Reagent

RIDADR

NONH for all modes of transport

Certificate of Analysis
Certificate of Origin
Aged stem cells reprogram their daily rhythmic functions to adapt to stress
Solanas G, et al.
Cell, 170, 678-692 (2017)
137 differential gene expression of in vitro-matured bovine oocytes with or without a polar body.
M. M. Pereira et al.
Reproduction, Fertility, and Development, 24(1) , 181-181 (2011)
Distinct degenerative phenotype of articular cartilage from knees with meniscus tear compared to knees with osteoarthritis
Rai MF, et al.
Osteoarthritis and Cartilage, 27, 945-955 (2019)
Bert Vanmechelen et al.
Scientific reports, 8(1), 11171-11171 (2018-07-26)
The family Arteriviridae harbors a rapidly expanding group of viruses known to infect a divergent group of mammals, including horses, pigs, possums, primates, and rodents. Hosts infected with arteriviruses present with a wide variety of (sub) clinical symptoms, depending on...
Limited correlation of shotgun metagenomics following host depletion and routine diagnostics for viruses and bacteria in low concentrated surrogate and clinical samples
Oechslin CP, et al.
Frontiers in Cellular and Infection Microbiology, 2018, 375-375 null
Articles
Transplex Whole Transcriptome Amplification (WTA2) exponentially amplifies RNA producing a double-stranded cDNA library while precisely maintaining differential levels of individual transcripts in test and reference samples.
Read More
The efficacy of amplification of small quantities of total RNA with the Complete Whole Transcriptome Amplification Kit (WTA2) was examined in this study.
Read More
Epigenetic modifications are thought to occur through two key interconnected processes—DNA methylation and the covalent modification of histones.
Read More
Protocols
Amplification products generated by the TransPlex® WTA and Complete WTA2 kits are suitable for microarray target for expression analyses, and can be incorporated into existing Illumina workflows.
Read More
Amplification products generated by the TransPlex® WTA and Complete WTA2 kits are suitable for microarray target for expression analyses, and can be readily integrated into existing NimbleGen workflows.
Read More
TransPlex WTA amplification product is suitable as microarray target for expression analysis on the Affymetrix platform, and can be incorporated into existing Affymetrix workflows
Read More
Amplification products generated by the TransPlex® WTA and Complete WTA2 kits are suitable for microarray target for expression analyses, and can be readily integrated into existing Agilent workflows
Read More
Related Content
Transplex Whole Transcriptome Amplification FAQs on topics including whole transcriptome steps, RNA source, including archival fixed tissue, library purification, quantitation of the product and downstream applications
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.